The PI3K/Akt/mTOR pathway is also implicated in the development of resistance to endocrine therapy, further supporting the rationale for mTOR inhibition in the treatment of ER + breast cancer [14, 15]. The gene discussed is AKT1; the disease is breast carcinoma.